Alterity Therapeutics
ATHE
14 hedge funds and large institutions have $494K invested in Alterity Therapeutics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
37% more capital invested
Capital invested by funds: $361K → $494K (+$133K)
8% more funds holding
Funds holding: 13 → 14 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$22.6K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$12.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.76K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.24K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$679 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Advisor Group
Phoenix,
Arizona
|
-$1.14K |
| 2 |
FC
Ferris Capital
Marlborough,
Massachusetts
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $409K | +$22.6K | +830 | +6% |
|
|
2
Citadel Advisors
Miami,
Florida
| $39K | +$5.24K | +193 | +16% |
|
|
3
Acadian Asset Management
Boston,
Massachusetts
| $13K | +$12.6K | +464 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $11K | +$9.76K | +359 | +945% |
|
|
AG
5
Advisor Group
Phoenix,
Arizona
| $7K | -$1.14K | -42 | -14% |
|
|
6
Bank of America
Charlotte,
North Carolina
| $4K | +$679 | +25 | +27% |
|
|
AIM
7
Advantage Investment Management
Cedar Rapids,
Iowa
| $3K | – | – | – |
|
8
Group One Trading
Chicago,
Illinois
| $2K | – | – | – |
|
|
NFG
9
Next Financial Group
Houston,
Texas
| $2K | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
|
LC
11
Landaas & Company
Milwaukee,
Wisconsin
| $2K | +$1.82K | +67 | New |
|
|
FC
12
Ferris Capital
Marlborough,
Massachusetts
| – | -$1K | -33 | Closed |
|
ATHE Hedge Fund Activity: Q3 2017 in Review
14 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q3 2017, worth a combined $494K — up 37% from $361K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ATHE positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $22.6K. The largest seller was Advisor Group, cutting an estimated $1.14K.
- 14 institutional investors held Alterity Therapeutics (ATHE) as of Q3 2017, up from 13 in Q2 2017.
- Funds reported $494K of Alterity Therapeutics stock for Q3 2017, up 37% quarter-over-quarter.
- 2 funds opened new Alterity Therapeutics positions in Q3 2017 and 1 closed out, a net change of +1 holder.
- The largest Alterity Therapeutics buyer in Q3 2017 was Morgan Stanley, an estimated $22.6K added.
- The largest Alterity Therapeutics seller in Q3 2017 was Advisor Group, an estimated $1.14K sold.
Based on aggregated 13F filings for Q3 2017.